Compare Recursion Pharmaceuticals Inc (RXRX) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Taskus Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.74B), while Taskus Inc trades at $7.59 (market cap $693.61M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.5× Taskus Inc's market cap, and Taskus Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | TASK | |
|---|---|---|
Market Cap | $1.74B | $693.61M |
Sector | Health | Technology |
52-Week High | $6.79 | $18.03 |
52-Week Low | $2.84 | $4.57 |
Enterprise Value | $1.26B | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
TaskUs (TASK) trades at $7.65, down 3.29% on the day, with mixed technical signals showing a neutral overall trend. Fundamentally, the company demonstrates strong profitability with 36.08% gross margins and 8.75% net income margin, while trading at attractive valuation multiples including a P/E of 6.59 and P/S of 0.58. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.28 expected, driven by 5% revenue growth to $308.9 million.
The stock presents value opportunity with analyst consensus target of $8.00 representing 4.6% upside, supported by 55% buy ratings. Key risks include client concentration and competitive pressures in the AI services space, while positive catalysts include continued AI adoption and new CFO leadership driving operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
